tiprankstipranks
Advertisement
Advertisement

JP:4884 Stock Latest News

Kringle Pharma Boosts Sales but Warns of Deeper Full-Year Losses
Company AnnouncementsKringle Pharma Boosts Sales but Warns of Deeper Full-Year Losses
7d ago
4884
Kringle Pharma Launches Additional Phase 3 Trial of Oremepermin Alfa in Acute Spinal Cord Injury
PremiumCompany Announcements
Kringle Pharma Launches Additional Phase 3 Trial of Oremepermin Alfa in Acute Spinal Cord Injury
24d ago
4884
Kringle Pharma narrows revenue gains but deepens losses in first half of FY2026
PremiumCompany Announcements
Kringle Pharma narrows revenue gains but deepens losses in first half of FY2026
3M ago
4884
Kringle Pharma Posts Narrower Quarterly Loss but Confirms Deep Full-Year Deficit Forecast
PremiumCompany Announcements
Kringle Pharma Posts Narrower Quarterly Loss but Confirms Deep Full-Year Deficit Forecast
6M ago
4884
Kringle Pharma Reports Increased Losses and Decline in Financial Position for FY 2025
PremiumCompany Announcements
Kringle Pharma Reports Increased Losses and Decline in Financial Position for FY 2025
9M ago
4884
Kringle Pharma’s Phase 3 Study on KP-100LI: A Potential Game-Changer for Vocal Fold Scar Treatment
PremiumCompany AnnouncementsKringle Pharma’s Phase 3 Study on KP-100LI: A Potential Game-Changer for Vocal Fold Scar Treatment
10M ago
4884
Kringle Pharma Expands Global Reach with New U.S. Subsidiary
Premium
Company Announcements
Kringle Pharma Expands Global Reach with New U.S. Subsidiary
10M ago
4884
Kringle Pharma Reports Decline in Nine-Month Financial Performance
Premium
Company Announcements
Kringle Pharma Reports Decline in Nine-Month Financial Performance
1y ago
4884
Kringle Pharma’s KP-100IT Receives U.S. FDA Orphan Drug Designation for Spinal Cord Injury
PremiumCompany Announcements
Kringle Pharma’s KP-100IT Receives U.S. FDA Orphan Drug Designation for Spinal Cord Injury
1y ago
4884
Kringle Pharma Reports Financial Decline in First Half of 2025
PremiumCompany Announcements
Kringle Pharma Reports Financial Decline in First Half of 2025
1y ago
4884
Kringle Pharma Releases Updated Analyst Report to Enhance Investor Insight
PremiumCompany Announcements
Kringle Pharma Releases Updated Analyst Report to Enhance Investor Insight
1y ago
4884
Kringle Pharma Reports Flat Sales and Continued Losses
PremiumCompany Announcements
Kringle Pharma Reports Flat Sales and Continued Losses
1y ago
4884
Kringle Pharma Releases New Analyst Report
PremiumCompany AnnouncementsKringle Pharma Releases New Analyst Report
2y ago
4884
Kringle Pharma Releases Insightful Analyst Report
Premium
Company Announcements
Kringle Pharma Releases Insightful Analyst Report
2y ago
4884
Kringle Pharma Reports Increased Sales Amid Losses
Premium
Company Announcements
Kringle Pharma Reports Increased Sales Amid Losses
2y ago
4884

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >